| Ytd | -17.06% | |
| 1y | -33.23% |
| Open | 2.16 | Prev Close | 2.14 | Low | 2.02 | High | 2.16 | Mkt Cap | 6.46M |
| Vol | 50.42K | Avg Vol | 64.77K | EPS | -1.61 | P/E | N/A | Forward P/E | 0.71 |
| Beta | -1.14 | Short Ratio | 0.76 | Inst. Own | 12.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-01 | 50-d Avg | 1.67 | 200-d Avg | 2.13 | 1yr Est | 13.00 |
Major M&A deals this week include: The Descartes Systems buys Tai, KKR nabs Ci FLAVORS, Skimmer
Biomerica, Inc. (NASDAQ:BMRA) ("Biomerica" or the "Company"), a developer and manufa
IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the
Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.
Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented
Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced t
Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under E
— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnost
Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.44) per share. This is a 8.33 percent incre
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or t
Biomerica (NASDAQ: BMRA - Get Free Report) is anticipated to post its results after the market close
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp
IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active
Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30%
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report)'s stock price crossed below its 200-day moving aver
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report) saw a significant growth in short interest during t
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report)'s stock price passed below its 200-day moving avera
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for a
IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report)'s share price passed below its 200-day moving avera
Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfo
Publication details large multicenter clinical trial demonstrating significant reductions in IBS sym
IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionC
IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider
Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arr
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Tru
Biomerica (NASDAQ:BMRA) reported $1.380 million in sales this quarter. This is a 23.63 percent decre
New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigg
10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dysp
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3145879/summary.html
PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step to
Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Pati
Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5%